Sun Pharma is showing a positive technical structure
SUNPHARMA Sun Pharma is showing a positive technical structure as the stock is currently trading at ₹1,880, comfortably above all four important EMAs: 21 EMA (₹1,827.9), 50 EMA (₹1,828.7), 100 EMA (₹1,837) and 200 EMA (₹1,818.3). This indicates improving bullish momentum and suggests that buyers are maintaining control. Recently, the stock witnessed a sharp recovery from the ₹1,740–1,760 support zone and moved towards ₹1,940–1,950, indicating strong buying interest. The ₹1,820–1,840 zone is now an important support area, where multiple EMAs are clustered. On the upside, ₹1,920–1,950 is an immediate resistance zone, followed by ₹2,000. Sustaining above the EMA cluster can keep the recovery structure positive, while a decisive breakout above resistance may strengthen the next upward move. Sun Pharma continues to benefit from strong domestic formulations and specialty medicines businesses. In Q2 FY27, revenue increased approximately 11.9% year-on-year, while India business grew 17.3%, reflecting healthy demand and product launches. Its specialty portfolio received another boost as the US FDA approved ILUMYA for treating adults with active psoriatic arthritis on October 30, 2026. However, the company reported pressure in its US business, with sales declining 8.2%, and EBITDA margin stood at 29.3%. One concern is the regulatory action involving its Assam facility, where ophthalmic product manufacturing was halted following quality-related observations; the company has submitted corrective measures for regulatory review. Overall, domestic growth and specialty medicines provide positive long-term support, but regulatory developments and US business performance remain important factors to monitor.




















